University of Southern California

Research

RFA-CA-18-029: Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)

Slots:                                                     1                             

Internal Deadline:                           Contact the Office of Research if interested

LOI:                                                        October 15, 2018                             

External Deadline:                          November 15, 2018, by 5:00 PM local time of applicant organization.

Award Information:                        Type:  Cooperative Agreement

Estimated Number of Awards: NCI intends to commit $5,000,000 in FY 2019 for up to 5 awards and $10,000,000 per year in subsequent years.

Anticipated Amount:  The requested budget must not exceed $625,000 in direct costs for year 1 and $1,250,000 in direct costs for subsequent years.

Submission Process:                     PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants

Materials to submit:

Link to Award:                                  https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-18-029.html

Who May Serve as PI:                    Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Purpose:

This Funding Opportunity Announcement (FOA) is one of two FOAs for the National Cancer Institute (NCI)-supported Cancer Prevention Clinical Trials Network (CP-CTNet). The purpose of CP-CTNet is to perform early phase clinical trials to evaluate the biologic effects of preventive agents and interventions and to determine clinically-relevant correlates in order to advance their development for cancer prevention.

CP-CTNet will support the following two types of components that will be individually awarded through the respective FOAs indicated below:

    • CP-CTNet Sites (this RFA), whose role will be to design, perform and report the results of early phase (phase 0-II) cancer prevention clinical trials.
    • Data Management, Auditing, and Coordinating Center (DMACC) (see RFA-CA-18-030), which will provide centralized data management and auditing of clinical trials data, as well as administrative support for all CP-CTNet awardees.

Each CP-CTNet Site will consist of a Lead Academic Organization (LAO) and Affiliated Organizations (AOs) that will work together to perform clinical trials.  Each CP-CTNet LAO will serve as the research hub for its group and will be the UG1 applicant institution. Each LAO will constitute a multi-institutional clinical trial group and provide the infrastructure to develop, implement, and analyze the studies. The Clinical trials will be performed either by the LAO and/or AOs within each CP-CTNet site or across the CP-CTNet sites (network-wide trials).

The overall goal of CP-CTNet is to perform early phase cancer prevention clinical trials to identify agents and interventions that can advance through the various phases of clinical development. Specific objectives are summarized below:

    • To efficiently design and conduct early phase clinical trials to assess the cancer preventive potential of a variety of different agents or strategies. Emphasis is on novel agents and interventions that target relevant pathways important in carcinogenesis.
    • To characterize the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlate these effects with clinical endpoints.
    • To develop further scientific insights into the mechanism of cancer prevention by the agent or strategy examined and to continue to develop novel potential markers as determinants of response.

Visit our Institutionally Limited Submission webpage for updates and other announcements.